![](/img/cover-not-exists.png)
2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation
Shapira-Frommer, R., Oza, A., Domchek, S.M., Balmana, J., Patel, M.R., Chen, L.M., Drew, Y., Burris, H.A., Korach, J., Flynn, M., Bowering, V.L., Morgan, M.A., Watkins, S.P., Simpson, D., Goble, S., MVolume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)31512-x
Date:
September, 2015
File:
PDF, 60 KB
english, 2015